Twitter Sinks as User Growth Slows; Gilead Sciences Outperforms Amgen, Celgene, and Biogen Idec.


Follow this company

Companies Mentioned

NYSE:TWTR / NASDAQ:GILD / NYSE:MGM / PK:FITX
04/30/2014 [ACCESSWIRE]

Twitter, Inc. (NYSE: TWTR) – For an in-depth report on Twitter, Inc. follow: www.BullTrends.com/stockquote/TWTR

Shares of Twitter closed up nearly 5% on Tuesday with about 28.1 million shares traded. However in after-hours trading shares dropped 11% after the company reported a slowdown in user growth in the first quarter. Twitter posted revenue of $250 million, up 119% year over year, but reported a quarterly loss of $132 million. It lost $27 million in the same quarter a year earlier.

Gilead Sciences Inc. (NASDAQ: GILD) - For an in-depth report on Gilead Sciences Inc. follow: www.BullTrends.com/stockquote/GILD

Shares of Gilead Sciences closed up 2.92% on Tuesday with nearly 16 million shares traded. The stock also saw gains on Monday after a Barron's article pointed out that last week the biopharmaceutical company had a nine day winning streak end but it continues to outperform other big biotech stocks like Amgen, Celgene, and Biogen Idec.

MGM Resorts International (NYSE: MGM) – For an in-depth report on MGM Resorts International follow: www.BullTrends.com/stockquote/MGM

Shares of MGM Resorts International closed up 8.51% on about 21.6 million shares traded. The stock was one of the biggest gainers on the NYSE and one of the most actively traded. Shares climbed as high as $24.99 during intra-day trading after the company reported better than anticipated earnings results.

Creative Edge Nutrition, Inc. (OTC: FITX) - For an in-depth report on Creative Edge Nutrition, Inc. follow: www.BullTrends.com/stockquote/FITX

Shares of FITX closed down 7.52% on Tuesday with nearly 50 million shares traded. The stock was one of the biggest decliners in the OTC market despite the company not releasing any significant news. On April 25th, the company announced the appointment of Dr. David L. Felten, M.D., Ph. D., to its Board of Directors.

 

Disclosure: BullTrends.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always conduct their own due diligence with any potential investment. Please read our report and visit our website, for complete risks and disclosures.

COMMENTS

Leave a comment...
 * 

Your Name
 *